Tagged with China

China China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard drugs and high drug prices. Fangda Partners’ Josh Shin explains how the new law strengthens penalties for counterfeit and substandard…

China Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the hope of becoming a world leader in pathological diagnostics in just a few years.   Our work at Absea over…

China China’s booming pharmaceutical industry has been rapidly expanding to become the second largest pharmaceutical market globally. The following are the top ten Chinese pharma companies from 2018, with revenues reaching over USD 1 billion.      Sinopharm Group CEO: Yong Liu HKEx 1099:HK Sinopharm Group, the largest member of the China…

China Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China in 2018; their ongoing efforts to develop more novel therapeutics; their ambitious internationalization strategy to bring their therapies to patients…

Singapore Vishal Doshi, founder and CEO of AUM Biosciences, shares his motivation behind establishing the company and his mission to build an ecosystem within AUM for a decentralized biotech innovation model; their focus on oncology and specifically small molecule cancer therapies; and the critical importance of the China market within their…

China Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the individual patient’s tumor microenvironment; their strategy to differentiate their approaches to in-licensing as well as combination plays within the area…

China Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the country over the past decades, its strengths as a diversified healthcare company offering not only pharmaceutical products but medical devices…

China John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific region; the solutions and services they offer, including their clinical development consultancy, ‘BioDesk’; as well as the exciting opportunities they…

4+7 China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.   Pharma companies in China are facing yet another intense race to the bottom on pricing. On the 24th of…

China Fangda Partners’ Josh Shin gives an overview of recent regulatory upgrades affecting the Chinese pharmaceutical industry.   On August 26, 2019, China enacted the Amended Drug Administration Law as part of its efforts to strengthen and streamline its regulation of the pharmaceutical industry. The amended law seeks to address prominent…

China Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary (GU) tumours and related disease because of the significant and oft-overlooked medical needs there; and the importance of building and…

China Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization), and their exciting international clinical development strategy for their three assets.   I realized that if I wanted to establish…